For instance, targeting the RNA-modifying enzyme METTL3 to upregulate the tumor-suppressive lncRNA LINC02418, which promotes PD-L1 degradation and synergizes with anti-PD-1 therapy (72). This evidence concerns the gene CD274 and neoplasm.